Tag: AHA 2019

Routine anticoagulation with rivaroxaban after TAVI harmful: GALILEO trial results

George Dangas (Mount Sinai Hospital, New York, USA) told delegates in a late-breaking trial session at the American Heart Association Scientific Sessions (AHA 2019;...

AHA 2019: ISCHEMIA shows no benefit for revascularisation in patients with...

The largest trial to date to compare revascularisation with a conservative strategy in patients with stable ischaemic heart disease has found no additional benefit...

AHA 2019: Preprocedural COLCHICINE-PCI finds a lowering of inflammation, but no...

Preprocedural administration of an oral colchicine load does not reduce the risk of myocardial injury or 30-day major adverse cardiovascular events (MACE) in patients...

AHA 2019: Endotronix shares data from in-human trial of Cordella pulmonary...

Endotronix has presented first-in-human data of the Cordella pulmonary artery pressure sensor System at the 2019 American Heart Association (AHA) Scientific Sessions (16–18 November,...